XARELTO
PeakNDAORALTABLET
Approved
Nov 2011
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2130
Data completeness
3/8 — Basic
IRA Negotiated
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XARELTO is an oral small-molecule anticoagulant approved in 2011 for thromboembolism prevention and treatment. The specific mechanism of action and indications are not detailed in available data, but the product is a cornerstone of Johnson & Johnson's cardiovascular portfolio. It represents a peak lifecycle product with sustained commercial significance.
$6.3BPart D
PeakStable
Peak-stage product with 6.6M annual claims and $6.3B spending indicates large, mature team with stable headcount across commercial, medical, and regulatory functions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2130)
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
Started Mar 2027
50 enrolled
Multiple Myeloma (MM)
Teclistamab In Waldenstrom's Macroglobulinemia
Started Feb 2027
24 enrolled
Waldenstrom's Macroglobulinemia
Computerized Decision Support to Prevent Stroke in Atrial Fibrillation
Started Dec 2026
2,500 enrolled
Atrial FibrillationStroke
Integrating the Guardian Spatial Emanator Within AVENIR II
Started Dec 2026
150,000 enrolled
Malaria
REal World MAIA UK OutcomEs
Started Dec 2026
300 enrolled
Myeloma
Worked on XARELTO at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.